Tag: light activation

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026

Laser-sharp Research / immunology, immunotherapy, laser-sharp research, light activation, liposomes, ML6600, pancreatic cancer, Photoimmunotherapy / May 20, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026 The research spotlight goes this month to Nimit Shah and the team from Dr. Girgis Obaid’s Lab Molecular Imaging and Optical Nanotherapeutics at University of Texas, Dallas. They developed and evaluated light-activated, verteporfin-containing liposomes for pancreatic cancer. This cancer is notoriously difficult to treat and more effective therapies are [...]

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026

Laser-sharp Research / apoptosis, BPD, cancer, ferroptosis, in vitro, in vivo, laser-sharp research, light activation, ML6600, ovarian cancer, Photoimmunotherapy, photosensitizer / January 28, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 The highlight of the month goes to teams of researchers led by Prof. Imran Rizvi at University of North Carolina at Chapel Hill. Their latest publication shows that certain light-activated therapy with BPD photosensitizer and ML6600 laser can induce ferroptosis-like cell death, including formation of lipid peroxides, in

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 Read More »

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy

Scientific papers / 690 nm, in vitro, in vivo, interleukin15, IR700, light activation, ML7710, National Cancer Institute, NIH, NIR, Photoimmunotherapy, PIT, tumor / August 31, 2025

Published in: Cancer Immunology, Immunotherapy Authors: Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Makoto Kano, Miyu Kano, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025

Laser-sharp Research / drug delivery, imaging, in vitro, laser-sharp research, light activation, ML6600, nanoparticles, Photodynamic therapy, Photoimmunotherapy, verteporfin / April 30, 2025

Gokalp et al. from University of Massachusetts and Tufts University constructed an innovative liquid metal nanoparticle platform, which has tumor cell targeting and enhanced encapsulation of verteporfin. Charactierization in vitro with the help of ML6600 laser showed effective in vitro phototoxicity.

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025 Read More »

Synthesis and evaluation of Aza-PLADIPYs: A novel class of cytotoxic agents

Scientific papers / 690 nm, in vitro, light activation, ML6600, photofrin, photosensitizer, phototoxicity / February 13, 2025

Published in: Results in Chemistry Authors: Tanvi A. Desphande, Andi Zeng, Michelle Young, Terrence Nicholson, Karen Luo, Sudip Timilsina, Bryan Q. Spring, Peter Müller, Neha Kulkarni, Swati Betharia, Ronny Priefer

Synthesis and evaluation of Aza-PLADIPYs: A novel class of cytotoxic agents Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

Laser-sharp Research / cancer, immunology, immunotherapy, in vitro, in vivo, laser-sharp research, LaserSharpResearch, light activation, ML7710, research, targeted therapies / January 22, 2025

Kobayashi et al. at NIH developed a therapy which results in tumor cell membrane destruction and immunogenic cell death. When activated with the ML7710 laser, there was proven efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – November 2024

Laser-sharp Research / 5-ALA, colorectal cancer, illumination, in vivo, laser-sharp research, light activation, Lung cancer, ML6600, noveltherapies, perfusion, Photodynamic therapy / November 19, 2024

Only 1 in 10 patients qualify for surgical resection of the pulmonary metastases – thus the management remains a significant clinical challenge. K. Ramadan et al. studied PDT and demonstrated the feasibility and safety of the procedure using 5-ALA and Chlorin e6 drugs with Modulight’s ML6600 laser.

Modulight Spotlights: LASER-SHARP RESEARCH – November 2024 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2024

Laser-sharp Research / cancer treatment, drug delivery, hypoxia, laser-sharp research, light activation, liposomes, ML8500, normoxia, University of Helsinki / October 24, 2024

Modulight Spotlights: LASER-SHARP RESEARCH – October 2024 This month, we are highlighting new findings published in RSC Materials Advances by Olga Lem, Roosa Kekki and researchers at Pharmaceutical Nanotechnology research group and Tampere University. The study provides key insights into the role of lipid oxidation in cargo release from light-activated liposomes. These spherical lipid vesicles can

Modulight Spotlights: LASER-SHARP RESEARCH – October 2024 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024

Laser-sharp Research / 672 nm, cancer, Cancer therapy, chemotherapy, Kill cancer, laser-sharp research, LaserSharpResearch, light activation, ML7710, prostate cancer, theranostics / July 26, 2024

New findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Using ML7710 laser at 672 nm for activation of the drug, they were able to dramatically improve therapeutic effect in prostate cancer models.

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Read More »